Compare · head to head
Bicara Therapeutics vs Castle Biosciences
Bicara Therapeutics ranks higher overall — 360 rank 43 vs 10.
Bicara Therapeutics leads on Quality (52 vs 32), Safety (41 vs 28) and Sentiment (57 vs 48). The two are close on Growth.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Biotechnology | Health Care Providers & Services |
| Size | Small | Medium |
| ISIN | US0554771032 | US14843C1053 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | — | |
| Ranks | ||
| 360 | 43 | 10 |
| Value | NR | 51 |
| Quality | 52 | 32 |
| Growth | 42 | 40 |
| Safety | 41 | 28 |
| Sentiment | 57 | 48 |
| Quality details | ||
| Profitability | 53 | 32 |
| Cash Truth | NR | 31 |
Bicara Therapeutics vs Janux TherapeuticsBicara Therapeutics vs Zenas BiopharmaBicara Therapeutics vs Vir BiotechnologyAdd a third stock →
Full analyses: Bicara Therapeutics · Castle Biosciences
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100